NYSE-listed #AltoNeuroscience has raised $120 million in a private placement that will be used to advance its recently acquired candidate for #treatmentresistantdepression (TRD) into a pivotal trials programme. #financing
Alto raises $120m for resistant depression programme
Alto Neuroscience has raised $120m that will fund pivotal trials of its recently acquired candidate for treatment-resistant depression.
buff.ly
March 17, 2026 at 3:00 PM
NYSE-listed #AltoNeuroscience has raised $120 million in a private placement that will be used to advance its recently acquired candidate for #treatmentresistantdepression (TRD) into a pivotal trials programme. #financing